Susquehanna International Group, LLP Oric Pharmaceuticals, Inc. Call Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 07, 2024	BUY	$8.04 - $16.03 $1.33 Million - $2.66 Million	165,900 Added 489.38%	199,800 $2.75 Million
Q4 2023 Feb 14, 2024	BUY	$5.41 - $9.43 $126,053 - $219,719	23,300 Added 219.81%	33,900 $311,000
Q3 2023 Nov 14, 2023	SELL	$6.05 - $9.28 $130,680 - $200,448	-21,600 Reduced 67.08%	10,600 $64,000
Q2 2023 Aug 11, 2023	BUY	$4.95 - $8.4 $58,410 - $99,120	11,800 Added 57.84%	32,200 $249,000
Q1 2023 May 16, 2023	SELL	$4.26 - $6.75 $402,996 - $638,550	-94,600 Reduced 82.26%	20,400 $116,000
Q4 2022 Feb 14, 2023	SELL	$2.41 - $5.89 $5,061 - $12,369	-2,100 Reduced 1.79%	115,000 $677,000
Q3 2022 Nov 14, 2022	SELL	$3.15 - $5.24 $81,585 - $135,716	-25,900 Reduced 18.11%	117,100 $375,000
Q2 2022 Aug 15, 2022	BUY	$2.7 - $7.07 $274,590 - $719,019	101,700 Added 246.25%	143,000 $641,000
Q1 2022 May 16, 2022	BUY	$4.54 - $16.1 $187,502 - $664,930	41,300 New	41,300 $221,000

124

66.6M

7.8K

700

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $336M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.